| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Multiple targets including iNOS (inducible nitric oxide synthase), HO-1 (heme oxygenase-1), and Nrf2 pathway. Bryonolic acid reduces NO by suppressing iNOS expression and induces HO-1 in an Nrf2-dependent manner.
|
|---|---|
| ln Vitro |
By preventing delayed hypersensitivity reactions and homologous passive skin allergy reactions, lichenic acid exhibits antiallergic effect. By preventing the expression of inducible nitric oxide synthase, bryosic acid lowers nitric oxide, suggesting anti-inflammatory properties [1]. In rat adrenal pheochromocytoma (PC12) cells, bryonolic acid counteracts the neurotoxicity caused by N-methyl-D-aspartate (NMDA), indicating that it may be a promising neuroprotective therapy for cerebral ischemia [1]. Bryonolic Acid (1-200 μM) suppresses the manufacture of tumor promoters that are cholesterol fatty acid ester and, in rat liver microsomes, acyl-CoA:cholesterol acyltransferase (ACAT) activity in a concentration-dependent way. With an IC50 of 12.6 µM, bryonolic acid inhibits ACAT in intact cancer cells[2]. Bryonolic acid has the ability to prevent MCF-7 MB-231, U87, and 3T3-EA cells from forming colonies and becoming invasive [2].
In vitro, Bryonolic acid shows anti-inflammatory and antioxidant activities. It reduces the inflammatory mediator NO by suppressing iNOS expression in LPS-activated RAW 264.7 macrophage cells. The compound induces the antioxidant protein HO-1 in an Nrf2-dependent manner. It protects PC12 cells against NMDA-induced apoptosis by inhibiting Ca²⁺ influx and regulating gene expression. Bryonolic acid inhibits cancer cell clonogenicity and invasiveness. |
| ln Vivo |
In a method that depends on the Nrf2-Keap1 pathway, bryonolic acid (500 mg/kg; intraperitoneal injection; once) efficiently promotes HO-1 [3].
In vivo, Bryonolic acid shows anti-inflammatory effects and induces HO-1 expression. The compound exerts anti-allergic activity by inhibiting homologous passive cutaneous anaphylaxis and delayed hypersensitivity in animal models. It shows neuroprotective potential in models of cerebral ischemia. |
| Enzyme Assay |
Non-cell binding assays for Bryonolic acid focus on enzyme inhibition rather than receptor binding. iNOS enzyme activity assays are performed using recombinant iNOS enzyme and L-arginine substrate. Enzyme and varying concentrations of Bryonolic acid (0.1-100 μM) are incubated at 37°C for 30-60 minutes. Nitrite production is measured using the Griess reaction. IC₅₀ values are calculated from inhibition curves. Alternatively, antioxidant activity is assessed by DPPH or ABTS radical scavenging assays.
|
| Cell Assay |
Cellular assays are performed using RAW 264.7 macrophage cells. Cells are stimulated with LPS (1 μg/mL) to induce iNOS expression and NO production. Bryonolic acid at concentrations of 1-50 μM is added simultaneously or pre-incubated. After 24 hours, culture supernatants are collected for nitrite measurement by Griess assay. iNOS and HO-1 protein expression is assessed by Western blotting. NF-κB activation is evaluated by reporter assays or nuclear translocation studies.
|
| Animal Protocol |
Animal/Disease Models: wild-type and Nrf2-/- mice [3]
Doses: 500 mg/kg Route of Administration: intraperitoneal (ip) injection; Experimental Results: HO-1 was induced in a manner dependent on the Nrf2-Keap1 pathway. In vivo studies are conducted in rodent models of inflammation. Bryonolic acid is administered orally or intraperitoneally at doses typically ranging from 5-50 mg/kg. For the passive cutaneous anaphylaxis model, mice are sensitized with IgE antibody and challenged with antigen; Bryonolic acid is administered prior to challenge. Vascular permeability is measured by Evans blue dye extravasation. Tissue HO-1 expression and inflammatory cytokine levels are assessed. |
| ADME/Pharmacokinetics |
Published pharmacokinetic data for Bryonolic acid are limited. As a triterpenoid compound, it is expected to have moderate oral bioavailability and extensive metabolism. The compound likely distributes to tissues and is eliminated via biliary excretion. Further pharmacokinetic studies are needed to determine half-life, protein binding, and metabolic pathways.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for Bryonolic acid are not available in the public domain. As a natural product with immunomodulatory activity, it is expected to have a reasonable safety profile at pharmacological doses. No significant acute toxicity has been reported in the literature. Standard toxicology studies would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
Brinoic acid is an organic hydroxyl compound. It has been reported to be found in Trichosanthes kirilowii, gourd, and other organisms with relevant data.
Bryonolic acid is a bioactive triterpenoid with multiple pharmacological activities including immunomodulatory, anti-inflammatory, antioxidant, anticancer, and neuroprotective properties. Its mechanism involves inhibition of iNOS, induction of HO-1 via Nrf2 activation, and modulation of inflammatory signaling pathways. The compound is being investigated as a potential therapeutic agent for inflammatory diseases, cancer, and cerebral ischemia. It is not approved for clinical use and is primarily used as a research tool. |
| Molecular Formula |
C30H48O3
|
|---|---|
| Molecular Weight |
456.71
|
| Exact Mass |
456.36
|
| CAS # |
24480-45-3
|
| PubChem CID |
472768
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
553.3±50.0 °C at 760 mmHg
|
| Flash Point |
302.5±26.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.557
|
| LogP |
8.99
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
33
|
| Complexity |
902
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@]12CC[C@@](C[C@H]1[C@@]3(CCC4=C([C@]3(CC2)C)CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)(C)C(=O)O
|
| InChi Key |
BHVJSLPLFOAMEV-FPLINDMSSA-N
|
| InChi Code |
InChI=1S/C30H48O3/c1-25(2)21-9-8-20-19(28(21,5)12-11-23(25)31)10-13-30(7)22-18-27(4,24(32)33)15-14-26(22,3)16-17-29(20,30)6/h21-23,31H,8-18H2,1-7H3,(H,32,33)/t21-,22+,23-,26+,27+,28+,29+,30-/m0/s1
|
| Chemical Name |
(2R,4aS,6aS,8aR,10S,12aS,14aS,14bR)-10-hydroxy-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,13,14,14b-tetradecahydropicene-2-carboxylic acid
|
| Synonyms |
UNII-J7YR6A878I; Bryonolic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1896 mL | 10.9479 mL | 21.8957 mL | |
| 5 mM | 0.4379 mL | 2.1896 mL | 4.3791 mL | |
| 10 mM | 0.2190 mL | 1.0948 mL | 2.1896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
